WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, announced that they will share positive data on IBSRELA® (tenapanor) via an oral presentation and two posters at the American College of Gastroenterology (ACG) annual meeting, being held October 20 to 25 in Vancouver, Canada. IBSRELA, discovered and developed by Ardelyx, is a first-in-class treatment that is currently approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.
"We are excited to share new data that adds to the robust body of evidence supporting IBSRELA and its differentiated mechanism of action, which is bringing much needed improvement to the lives of people living with IBS-C," said Laura Williams, MD, MPH, chief medical officer of Ardelyx. "Physicians and other professionals attending ACG 2023 work with IBS-C patients every day and know all too well how challenging this condition can be. We are hopeful that this data increases the enthusiasm we have already seen for this new treatment and the potential it has to reduce the burden of IBS-C symptoms."
"The findings being presented today on the median time to first response with IBSRELA are particularly meaningful for patients seeking relief from the pain, bloating and discomfort associated with IBS-C and demonstrate how important it is to give patients a fair trial on IBSRELA," added Brian E. Lacy, M.D., Ph.D., Professor of Medicine, Mayo Clinic. "While a significant proportion of patients will have an early positive response to IBSRELA treatment, patient response rates increase with continued therapy. This finding underscores the importance of maintaining treatment beyond 3-4 weeks, so as not to miss those patients who will improve with time."
- The oral presentation, titled Tenapanor Treatment Success for IBS-C Symptoms Increases with Duration of Therapy led by Dr. Brian E. Lacy, Dr. Yang Yang and Dr. David P. Rosenbaum, will share findings from a pooled analysis of the phase 2b and phase 3 T3MPO studies of IBSRELA in adult patients. These studies looked at the effects of the drug on abdominal pain and other IBS-C symptoms. The new post-hoc data presented today evaluate the time to onset of tenapanor effect on bowel function and abdominal symptoms in adult patients with IBS-C. The researchers concluded that these patients experience a relatively quick onset of symptom relief under tenapanor treatment and that weekly response rates continued to increase with treatment duration.
- The first poster to be presented at the ACG meeting, titled Tenapanor Can Improve ...